Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pirow Bekker

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Seminars in Arthritis and Rheumatism|April 29, 2022
The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over timeJohn H Stone, P Jane McDowell, David R W Jayne, et al.
The Lancet. Rheumatology|January 22, 2024
The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trialNaomi J Patel, David R W Jayne, Peter A Merkel, et al.
Plos One|March 26, 2013
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's diseaseSatish Keshav, Tomáš Vaňásek, Yaron Niv, et al.
Mediators of Inflammation|October 13, 2015
CCR9 Antagonists in the Treatment of Ulcerative ColitisPirow Bekker, Karen Ebsworth, Matthew J Walters, et al.
Journal of the American Society of Nephrology : JASN|April 13, 2017
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated VasculitisDavid R W Jayne, Annette N Bruchfeld, Lorraine Harper, et al.
Plos One|October 22, 2016
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical StudyPirow Bekker, Daniel Dairaghi, Lisa Seitz, et al.
Plos One|January 5, 2019
Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical StudyPirow Bekker, Daniel Dairaghi, Lisa Seitz, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2010
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseMatthew J Walters, Yu Wang, Nu Lai, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 2, 2012
Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complicationsTimothy J Sullivan, Daniel J Dairaghi, Antoni Krasinski, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Seminars in Arthritis and Rheumatism|April 29, 2022
The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over timeJohn H Stone, P Jane McDowell, David R W Jayne, et al.
The Lancet. Rheumatology|January 22, 2024
The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trialNaomi J Patel, David R W Jayne, Peter A Merkel, et al.
Plos One|March 26, 2013
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's diseaseSatish Keshav, Tomáš Vaňásek, Yaron Niv, et al.
Mediators of Inflammation|October 13, 2015
CCR9 Antagonists in the Treatment of Ulcerative ColitisPirow Bekker, Karen Ebsworth, Matthew J Walters, et al.
Journal of the American Society of Nephrology : JASN|April 13, 2017
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated VasculitisDavid R W Jayne, Annette N Bruchfeld, Lorraine Harper, et al.
Plos One|October 22, 2016
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical StudyPirow Bekker, Daniel Dairaghi, Lisa Seitz, et al.
Plos One|January 5, 2019
Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical StudyPirow Bekker, Daniel Dairaghi, Lisa Seitz, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2010
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseMatthew J Walters, Yu Wang, Nu Lai, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 2, 2012
Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complicationsTimothy J Sullivan, Daniel J Dairaghi, Antoni Krasinski, et al.
Pageof 3